Jabre Capital Partners’s Ionis Pharmaceuticals IONS Stock Holding History

Jabre Capital Partners’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-35,000	Closed	-$1.8M	–	59
2018 Q3	$1.8M	Sell	35,000 -55,000	-61%	-$2.58M	0.6%	43
2018 Q2	$3.75M	Buy	+90,000	New	+$3.99M	0.25%	31
2016 Q4	–	Sell	-70,000	Closed	-$2.56M	–	112
2016 Q3	$2.56M	Sell	70,000 -9,500	-12%	-$297K	0.35%	66
2016 Q2	$1.81M	Buy	79,500 +39,500	+99%	+$1.27M	0.55%	57
2016 Q1	$1.62M	Buy	+40,000	New	+$1.62M	0.26%	83

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

WRF

Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Jabre Capital Partners's IONS Position: Q4 2018 in Review

Jabre Capital Partners sold out of Ionis Pharmaceuticals (IONS) in Q4 2018, closing a stake of 35,000 shares — an estimated $1.8M sold.

Jabre Capital Partners first reported a position in IONS in Q1 2016 and held it in 5 quarters. The position peaked at $3.75M in Q2 2018. 329 funds tracked by Wall St. Rank hold IONS as of Q4 2018.

Jabre Capital Partners reported no remaining Ionis Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Jabre Capital Partners sold 35,000 Ionis Pharmaceuticals shares in Q4 2018, an estimated $1.8M.
Jabre Capital Partners first reported a position in Ionis Pharmaceuticals in Q1 2016 and held it in 5 quarters.
Jabre Capital Partners's Ionis Pharmaceuticals position peaked at $3.75M in Q2 2018.
329 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2018.

Based on Jabre Capital Partners's 13F filing for Q4 2018, filed 14 Feb 2019.